Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

22P - Adding anlotinib in gradual or local progression on first-line EGFR-TKIs for advanced non-small cell lung cancer: A single-arm, multicenter, phase II trial


31 Mar 2023


Poster Display session


Huajun Chen


Journal of Thoracic Oncology (2023) 18 (4S): S35-S88.


H. Chen1, Y. Hu2, Y. Fan3, G. Wu4, S. Cang5, Y. Yang6, N. Yang7, R. Ma8, G. Jing9, A. Liu10, X. Xu11, S. Tang12, Y. Cheng13, Y. Yu14, Y. Wu15

Author affiliations

  • 1 Guangzhou/CN
  • 2 Hubei Cancer Hospital, Wuhan/CN
  • 3 Cancer Hospital of the University of Chinese Academy of Sciences/ Zhejiang Cancer Hospital, Hangzhou/CN
  • 4 Meizhou People's Hospital, Meizhou/CN
  • 5 Henan Provincial People's Hospital, Zhengzhou/CN
  • 6 The third people's hospital of Chendu, Chendu/CN
  • 7 Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha/CN
  • 8 Liaoning Cancer Hospital, Shenyang/CN
  • 9 Inner Mongolia Autonomous Region People's Hospital, Huhhot/CN
  • 10 The Second Affiliated Hospital of Nanchang University, Nanchang/CN
  • 11 Renmin Hospital of Wuhan University/ Hubei General Hospital, Wuhan/CN
  • 12 The first people's hospital of Neijiang, Neijiang/CN
  • 13 Jilin Cancer Hospital, Changchun/CN
  • 14 Harbin Medical University Cancer Hospital, Harbin/CN
  • 15 Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou/CN


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 22P


Anlotinib plus EGFR-TKIs continuation was a potential treatment strategy in selected advanced non-small cell lung cancer (NSCLC) after disease progression in first-line EGFR-TKIs. This study aimed to evaluate the efficacy and safety of combined EGFR-TKIs and anlotinib.


The trial aimed to enroll 120 patients after gradual or local progression in EGFR-TKIs treatment. All patients were treated with oral anlotinib 12 mg daily for 14 days every three weeks until disease progression or intolerable toxicity. The primary end-point was progression-free survival (PFS). The secondary end-points were 6 months and 12 months PFS rate, Overall response rate (ORR), disease control rate (DCR), overall survival (OS) and safety.


From July 08, 2019 to December 15, 2022 the enrollment was completed, including 109 patients with gradual progression. Up to December 31, 2022, 114 patients were available for efficacy assessment (105 patients had confirmed evaluation). Median PFS of combined anlotinib and EGFR-TKIs treatment was 9.2 months (95% CI, 6.6–11.6). Confirmed ORR was 5.7% and DCR was 92.4%. The PFS rate at 6 and 12 months was 66.3% and 36.7% respectively. Safety assessment was available in 116 patients, 94% (109/116) patients were reported treatment related adverse events (TRAEs). The incidence of grade 3 or 4 TRAEs was 36.2% (42/116) and the treatment-related serious adverse event (SAE) was 7.8% (9/116). The common TRAEs were diarrhea (47.4%), hypertension (42.2%), proteinuria (39.7%), and hypertriglyceridemia (24.1%). 22.4% (26/116) of patients experienced anlotinib dose reduction.


EGFR-TKIs plus anlotinib demonstrated meaningful clinical control in advanced NSCLC after gradual or local progression in first-line EGFR-TKIs. And the toxicity was clinically manageable.

Clinical trial identification


Legal entity responsible for the study

Guangdong Association of Clinical Trials.


Chia Tai Tianqing Pharmaceutical Group Co., Ltd.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.